TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2190464
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IS-5-MN), 20 mg
Study: 688734
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg N acetate and 50 μg EE2 (Minovlar)
Study: 688734
Drug: 1.05 mg
Normalized name: thiamine 1.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.05 mg N (Noriday)
Study: 688734
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg N acetate and 50 μg EE2 (Gynovlar)
Study: 688734
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg N with 50 μg EE2 (intravenous preparation)
Study: 25418575
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behaviour Therapy (ICBT)
Study: 21377690
Drug: Usual pharmacotherapy
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual pharmacotherapy plus aerobic exercise (N = 22)
Study: 21377690
Drug: Usual pharmacotherapy
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual pharmacotherapy (N = 11)
Study: 16995333
Drug: Almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 12.5 mg with ethanol (target plasma concentration 0.8 g/kg)
Study: 16995333
Drug: Almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 12.5 mg alone
Study: 12891200
Drug: Enoxaparin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 100 IU/kg twice daily (n = 220)
Study: 12891200
Drug: Tinzaparin, 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin, 175 IU/kg once daily (n = 218)
Study: 6624694
Drug: L-carnitine oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine oral treatment (2 g/day)
Study: 30803131
Drug: DFM30 (tinted
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFM30 (tinted daily SPF‐30 facial moisturizer)
Study: 21544087
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg anthocyanins twice daily
Study: 18629569
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of calcium plus 800 IU of vitamin D
Study: 18629569
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of calcium
Study: 17244291
Drug: Cash and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash and Counseling consumers (treatment group)
Study: 2695287
Drug: 50 ug
Normalized name: DIGOXIN 250 ug ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ug ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Study: 2695287
Drug: 35 ug
Normalized name: ETHYNODIOL DIACETATE 1 mg / ETHINYL ESTRADIOL 35 ug ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 ug ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Study: 2695287
Drug: 35 ug
Normalized name: ETHYNODIOL DIACETATE 1 mg / ETHINYL ESTRADIOL 35 ug ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 ug ethinyl estradiol (EE) and 0.5 mg norethindrone (NE)
Study: 324773
Drug: Flurbiprofen (150‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (150‐200 mg daily)
Study: 329422
Drug: Indomethacin (75‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75‐100 mg daily)
Study: 27869488
Drug: co-phenylcaine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-phenylcaine nasal spray
Study: 27869488
Drug: placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo nasal spray
Study: 23348881
Drug: Shorter dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter dialysis treatment times
Study: 19213681
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with zoledronic acid (4 mg IV every 6 months for 3 years)
Study: 17159195
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy without zoledronic acid
Study: 19213681
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg orally daily)
Study: 19213681
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg orally daily)
Study: 19213681
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with zoledronic acid
Study: 12843161
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg mixed esters)
Study: 17223994
Drug: Nandrolone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone (200 mg nandrolone decanoate)
Study: 17223994
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml arachis oil vehicle)
Study: 1835830
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution
Study: 8201953
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) insulin delivery
Study: 2740091
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir in modified aqueous cream (ACV-MAC)
Study: 2740091
Drug: Modified aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified aqueous cream vehicle (control)
Study: 129002
Drug: Propranolol (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80-160 mg/day)
Study: 30230409
Drug: Agilepristone (AGL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agilepristone (AGL) 10 mg/kg SC q24h for two consecutive days
Study: 30230409
Drug: Agilepristone (AGL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agilepristone (AGL) + Misoprostol (MIS) 200 µg/cat PO q12h until abortion
Study: 30230409
Drug: Misoprostol (MIS)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (MIS) 200 µg/cat PO q12h until abortion
Study: 30230409
Drug: Misoprostol (MIS)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (MIS) 400 µg/cat PO q12h until abortion
Study: 19327412
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (no revascularization)
Study: 16048810
Drug: External Qi-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Qi-therapy (QT)
Study: 16173532
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control therapy
Study: 12528607
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (200 micrograms daily)
Study: 9483167
Drug: Cabergoline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.25 to 4 mg once daily)
Study: 9483167
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 to 600 mg/day)
Study: 2229496
Drug: Lidocaine/prilocaine (EMLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine (EMLA) cream (n = 58)
Study: 2229496
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (n = 25)
Study: 11413274
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg daily)
Study: 11413274
Drug: Vigabatrin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (2000 mg daily)
Study: 29572094
Drug: ARC-AAT (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARC-AAT (4.0 mg/kg)
Study: 26998949
Drug: Individual Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Nutrition Therapy and Exercise Regime (alternate weekly visits from a physical therapist and dietitian)
Study: 26998949
Drug: Individual Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Nutrition Therapy and Exercise Regime
Study: 22251436
Drug: Maraviroc 300
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg BID for 12 weeks
Study: 15727644
Drug: Q-switched Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched Nd:YAG laser (three treatment sessions)
Study: 19105432
Drug: Calcitonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (50 units, intramuscular, 2 times each week), Caltrate D (1 tablet, orally, once daily), Alfacalcidol Soft Capsules (0.5 units, orally, once daily)
Study: 16497637
Drug: Individualized nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutrition and lifestyle counselling (at least twice a year)
Study: 14502777
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation therapy (BCT)
Study: 10321561
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (DP)‐D. farinae (DF) 50/50 extract, cumulative dose of about 104000 IR over 24 months.
Study: 1658863
Drug: Glycerol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol treatment
Study: 1658863
Drug: No anti-edema
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-edema treatment
Study: 21625426
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 µg/kg body weight/day for 10 days)
Study: 3064972
Drug: Controlled-release diazepam
Normalized name: diazepam Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release diazepam (10 mg once daily)
Study: 3064972
Drug: Conventional diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diazepam (5 mg 3-times daily)
Study: 29891606
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g every day (QD) for 7 doses
Study: 29891606
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g every other day (QOD) for 3 doses
Study: 26936043
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug trials
Study: 23733372
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg
Study: 23733372
Drug: Pasireotide 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 900 μg
Study: 23733372
Drug: Pasireotide 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 1200 μg
Study: 16603776
Drug: plain lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: plain lubricant gel
Study: 9702620
Drug: Nicardipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 5 mg i.v. rapid infusion
Study: 9702620
Drug: Nicardipine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 10 to 15 mg i.v. rapid infusion
Study: 9702620
Drug: Nicardipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 1.25 to 5 mg i.v. bolus
Study: 9702620
Drug: Nicardipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 5 mg i.v. bolus
Study: 9702620
Drug: Nicardipine 2.5
Normalized name: niCARdipine 2.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 2.5 to 5 mg i.v. bolus with labetalol 10 mg i.v.
Study: 9702620
Drug: Nicardipine 2.5
Normalized name: niCARdipine 2.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 2.5 mg i.v. bolus with labetalol 10 mg i.v.
Study: 2239218
Drug: Amoxicillin/clavulanate for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate for 4 weeks
Study: 7045314
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose prednisone therapy (2 mg/kg/day)
Study: 7045314
Drug: Pulse methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulse methylprednisolone therapy (30 mg/kg/day, not to exceed 1 gm/day) followed by prednisone (2 mg/kg/day)
Study: 24890542
Drug: Prasugrel 60-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60-mg loading dose (n = 25)
Study: 24890542
Drug: Ticagrelor 360-mg
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 360-mg loading dose (n = 25)
Study: 22865589
Drug: Preoperative topical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative topical antimicrobial decolonization with a 5-day regimen of chlorhexidine skin rinses and intranasal mupirocin coupled with standard perioperative systemic antimicrobial prophylaxis
Study: 15531906
Drug: Pegfilgrastim (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (12 mg single dose)
Study: 15531906
Drug: Unconjugated G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconjugated G-CSF (8.5 mug/kg/day)
Study: 15531906
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions post high-dose melphalan (200 mg/m2) and autografting
Study: 15013248
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR 300 mg/day
Study: 10990148
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (6.7 microg/kg/day for 12 weeks)
Study: 7608429
Drug: Aspirin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (200 mg/day)
Study: 7608429
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus regular heparin (400 IU/kg body weight per day intravenously)
Study: 7608429
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus low molecular weight heparin (214 UIC/kg anti‐Xa twice daily subcutaneously)
Study: 23281243
Drug: Disease-modifying antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying antirheumatic drugs (DMARDs)
Study: 606780
Drug: Whole-virus vaccines
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus vaccines (400 CCA units/0.5 ml or 200 CCA units/0.25 ml)
Study: 606780
Drug: Ether-extracted, subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ether-extracted, subunit vaccines (with or without 1.5 mg of A1PO4/0.5 ml)
Study: 606780
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of ether-extracted, subunit virus vaccine with Hsw1N1 antigen
Study: 606780
Drug: Dosage regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage regimen of two doses administered at least four weeks apart
Study: 30192341
Drug: Topical extra
Normalized name: GLYCERIN 13.226 g in 100 mL TOPICAL EXTRACT [WELLAGE 4D Gold Essence]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical extra virgin olive oil for massaging
Study: 1696799
Drug: Piroxicam gel
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam gel
Study: 30192341
Drug: Routine drugs
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drugs alone
Study: 21395680
Drug: Tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (5 mg/mL)
Study: 17457134
Drug: Sodium parecoxib
Normalized name: parecoxib sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium parecoxib (1 mg/kg)
Study: 15764246
Drug: 5'-DFUR administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR administration
Study: 7751425
Drug: IMDUR 60-mg
Normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMDUR 60-mg tablets
Study: 7751425
Drug: 5-ISMN 60-mg
Normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ISMN 60-mg solution
Study: 7751425
Drug: IMDUR 60-mg
Normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMDUR 60-mg tablets with food
Study: 7751425
Drug: IMDUR 60-mg
Normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMDUR 60-mg tablets under fasted conditions
Study: 31174889
Drug: ipafricept (IPA)
Normalized name: IPA
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipafricept (IPA) in combination with carboplatin (C) and paclitaxel (P)
Study: 22791118
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS), treated once daily for 4 weeks.
Study: 22791118
Drug: Placebo, treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, treated once daily for 4 weeks.
Study: 15361093
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection followed by graded pneumatic dilatation (PD) with 30 mm balloons
Study: 7947417
Drug: Haloperidol treatment
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol treatment (on medication)
Study: 7947417
Drug: Drug-free baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free baseline (off medication)
Study: 2522902
Drug: Short-acting GnRH
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting GnRH agonist (100-500 micrograms daily)
Study: 2976414
Drug: Long-acting GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting GnRH agonist (3.2 mg bolus)
Study: 2976414
Drug: Combined GnRH-agonist/gonadotrophin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined GnRH-agonist/gonadotrophin stimulation
Study: 27424879
Drug: Endodontic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic therapy followed by extraction (Group B)
Study: 22672237
Drug: 0.15 mol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mol L(‐1) HCl infusion
Study: 18573823
Drug: Atorvastatin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin as add-on therapy to interferon-beta 1b
Study: 16085593
Drug: mu-opioid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mu-opioid receptor binding in bulimic subjects
Study: 8983446
Drug: Serum IL-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL-4 concentration (0.06 ng/ml)
Study: 8983446
Drug: Serum GM-CSF
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum GM-CSF concentration (4.4 pg/ml)
Study: 8195848
Drug: Brodimoprim (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim (single dose)
Study: 8195848
Drug: Co-trimoxazole (trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (trimethoprim 160 mg + sulphamethoxazole 800 mg every 12 hours)
Study: 8195848
Drug: Erythromycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (600 mg three times a day)
Study: 3763654
Drug: 2% fusidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% fusidic acid plus 0.1% betamethasone cream
Study: 3763654
Drug: 0.1% gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% gentamicin plus 0.1% betamethasone cream
Study: 25924781
Drug: CPAP (PEEP:
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP (PEEP: 5 cm H2O, flow: 15 L/min, FiO2: 33 %) three times per week during hemodialysis sessions
Study: 22177779
Drug: Selective endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective endoscopic treatment of non-refluxing contralateral ureters (NRCU) in patients deemed at high risk (H2 or H3)
Study: 22177779
Drug: Observation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of non-refluxing contralateral ureters (NRCU) without treatment
Study: 21400196
Drug: 20,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 IU vitamin D(3) weekly and 500 mg calcium daily for 96 weeks
Study: 21400196
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and 500 mg calcium daily for 96 weeks
Study: 16469753
Drug: CVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD regimen (cisplatin 30 mg/m2 on days 1-3, vindesine 2.5 mg/m2 on day 1, dacarbazine 250 mg/m2 on days 1-3)
Study: 7016150
Drug: Alprenolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (5-10 mg intravenously followed by 200 mg orally twice a day for one year)
Study: 7016150
Drug: Placebo (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5-10 mg intravenously followed by placebo orally twice a day for one year)
Study: 26605836
Drug: Aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2.0 mg)
Study: 26048069
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) therapy with lidocaine and bupivacaine
Study: 23835559
Drug: Modern knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern knee implant
Study: 23835559
Drug: Traditional knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional knee implant
Study: 19454394
Drug: Twice-daily insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily insulin lispro mix 75/25 plus metformin
Study: 19454394
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily insulin lispro mix 50/50 plus metformin
Study: 15531001
Drug: Rosuvastatin 10-40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10-40 mg
Study: 15531001
Drug: Atorvastatin (milligram-equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (milligram-equivalent doses)
Study: 15531001
Drug: Simvastatin (milligram-equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (milligram-equivalent or higher doses)
Study: 15531001
Drug: Pravastatin (milligram-equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (milligram-equivalent or higher doses)